Associations between anticholinergic burden and adverse health outcomes in Parkinson disease | ||
| dc.conicet.organizacion | University of Ottawa | |
| dc.conicet.organizacion | University of Pennsylvania | |
| dc.conicet.organizacion | University of Pennsylvania | |
| dc.conicet.organizacion | University of Pennsylvania | |
| dc.conicet.organizacion | University of Ottawa | |
| dc.conicet.organizacion | University of Ottawa | |
| dc.conicet.organizacion | Cerner Corporation | |
| dc.conicet.organizacion | Cerner Corporation | |
| dc.conicet.organizacion | University of Ottawa | |
| dc.conicet.organizacion | University of Ottawa | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas | |
| dc.conicet.organizacion | University of Ottawa | |
| dc.conicet.organizacion | Risk Sciences International | |
| dc.conicet.organizacion | University of Ottawa | |
| dc.conicet.organizacion | Risk Sciences International | |
| dc.contributor.author | Crispo, James A. G. | |
| dc.contributor.author | Willis, Allison W. | |
| dc.contributor.author | Thibault, Dylan P. | |
| dc.contributor.author | Fortin, Yannick | |
| dc.contributor.author | Hays, Harlen D. | |
| dc.contributor.author | McNair, Douglas S. | |
| dc.contributor.author | Bjerre, Lise M. | |
| dc.contributor.author | Kohen, Dafna E. | |
| dc.contributor.author | Pérez Lloret, Santiago | |
| dc.contributor.author | Mattison, Donald R. | |
| dc.contributor.author | Krewski, Daniel | |
| dc.date.issued | 2016-03 | |
| dc.description.abstract | Background Elderly adults should avoid medications with anticholinergic effects since they may increase the risk of adverse events, including falls, delirium, and cognitive impairment. However, data on anticholinergic burden are limited in subpopulations, such as individuals with Parkinson disease (PD). The objective of this study was to determine whether anticholinergic burden was associated with adverse outcomes in a PD inpatient population. Methods Using the Cerner Health Facts1database, we retrospectively examined anticholinergic medication use, diagnoses, and hospital revisits within a cohort of 16,302 PD inpatients admitted to a Cerner hospital between 2000 and 2011. Anticholinergic burden was computed using the Anticholinergic Risk Scale (ARS). Primary outcomes were associations between ARS score and diagnosis of fracture and delirium. Secondary outcomes included associations between ARS score and 30-day hospital revisits. Results Many individuals (57.8%) were prescribed non-PD medications with moderate to very strong anticholinergic potential. Individuals with the greatest ARS score (4) were morelikely to be diagnosed with fractures (adjusted odds ratio (AOR): 1.56, 95% CI: 1.29-1.88) and delirium (AOR: 1.61, 95% CI: 1.08-2.40) relative to those with no anticholinergic burden. Similarly, inpatients with the greatest ARS score were more likely to visit the emergency department (adjusted hazard ratio (AHR): 1.32, 95% CI: 1.10-1.58) and be readmitted (AHR: 1.16, 95% CI: 1.01-1.33) within 30-days of discharge. Conclusions We found a positive association between increased anticholinergic burden and adverse outcomes among individuals with PD. Additional pharmacovigilance studies are needed to better understand risks associated with anticholinergic medication use in PD. | es |
| dc.description.fil | Fil: Crispo, James A. G.. University of Ottawa; Canadá. University of Pennsylvania; Estados Unidos | |
| dc.description.fil | Fil: Willis, Allison W.. University of Pennsylvania; Estados Unidos | |
| dc.description.fil | Fil: Thibault, Dylan P.. University of Pennsylvania; Estados Unidos. University of Ottawa; Canadá | |
| dc.description.fil | Fil: Fortin, Yannick. University of Ottawa; Canadá | |
| dc.description.fil | Fil: Hays, Harlen D.. Cerner Corporation; Estados Unidos | |
| dc.description.fil | Fil: McNair, Douglas S.. Cerner Corporation; Estados Unidos | |
| dc.description.fil | Fil: Bjerre, Lise M.. University of Ottawa; Canadá | |
| dc.description.fil | Fil: Kohen, Dafna E.. University of Ottawa; Canadá | |
| dc.description.fil | Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina | |
| dc.description.fil | Fil: Mattison, Donald R.. University of Ottawa; Canadá. Risk Sciences International; Canadá | |
| dc.description.fil | Fil: Krewski, Daniel. University of Ottawa; Canadá. Risk Sciences International; Canadá | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Crispo, James A. G.; Willis, Allison W.; Thibault, Dylan P.; Fortin, Yannick; Hays, Harlen D.; et al.; Associations between anticholinergic burden and adverse health outcomes in Parkinson disease; Public Library of Science; Plos One; 11; 3; 3-2016; 21-28; e0150621 | es |
| dc.identifier.eissn | 1932-6203 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/84674 | |
| dc.journal.ciudad | San Francisco | es |
| dc.journal.number | 3 | es |
| dc.journal.pagination | 21-28; e0150621 | es |
| dc.journal.pais | Estados Unidos | es |
| dc.journal.title | Plos One | es |
| dc.journal.volume | 11 | es |
| dc.language.iso | eng | es |
| dc.publisher | Public Library of Science | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1371/journal.pone.0150621 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150621 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | Enfermedad de Parkinson | es |
| dc.subject | Medicamentos Anticolinérgicos | es |
| dc.subject | Delirio | es |
| dc.subject | Fracturas | es |
| dc.subject.classification | Epidemiología | es |
| dc.subject.classification | Ciencias de la Salud | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Associations between anticholinergic burden and adverse health outcomes in Parkinson disease | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.b60f5f62-0276-44c8-b5d2-af15a9c9884e_A.pdf
- Tamaño:
- 268.54 KB
- Formato:
- Adobe Portable Document Format